Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.110
+0.050 (4.72%)
Dec 20, 2024, 4:00 PM EST - Market closed
Barinthus Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 14.97 | 0.8 | 44.7 | 0.27 | 4.82 | 6.85 |
| Revenue Growth (YoY) | 106.21% | -98.21% | 16580.22% | -94.44% | -29.57% | - |
| Cost of Revenue | 45.09 | 44.87 | 42.35 | 20.37 | 14.39 | 29.84 |
| Gross Profit | -30.12 | -44.07 | 2.35 | -20.1 | -9.57 | -23 |
| Selling, General & Admin | 40.55 | 39.79 | 6.47 | 25.12 | 10.48 | 2.67 |
| Research & Development | -7.22 | -3.46 | -1.24 | -4 | -3.28 | -2.98 |
| Operating Expenses | 32.33 | 36.33 | 5.23 | 21.12 | 7.2 | -0.31 |
| Operating Income | -62.45 | -80.4 | -2.87 | -41.22 | -16.77 | -22.69 |
| Interest Expense | -0.05 | -0.03 | -0.02 | -2.67 | -3.6 | -0.13 |
| Interest & Investment Income | 2.61 | 2.88 | 3.1 | 0 | - | 0.04 |
| Currency Exchange Gain (Loss) | - | - | - | 0.21 | 0.45 | - |
| Other Non Operating Income (Expenses) | 0.82 | 1.08 | 0.57 | 6.33 | 2.08 | 0.08 |
| EBT Excluding Unusual Items | -59.07 | -76.47 | 0.78 | -37.35 | -17.84 | -22.7 |
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0 |
| Other Unusual Items | 0.32 | -0.06 | 0.07 | -13.79 | - | - |
| Pretax Income | -58.75 | -76.52 | 0.85 | -51.14 | -17.84 | -22.7 |
| Income Tax Expense | -0.87 | -3.08 | -4.47 | -0.03 | 0.1 | - |
| Earnings From Continuing Operations | -57.88 | -73.45 | 5.32 | -51.11 | -17.93 | -22.7 |
| Minority Interest in Earnings | 0.06 | 0.1 | 0.02 | 0.25 | 0.23 | 1.97 |
| Net Income | -57.83 | -73.35 | 5.34 | -50.87 | -17.71 | -20.73 |
| Net Income to Common | -57.83 | -73.35 | 5.34 | -50.87 | -17.71 | -20.73 |
| Shares Outstanding (Basic) | 39 | 38 | 37 | 26 | 8 | 0 |
| Shares Outstanding (Diluted) | 39 | 38 | 38 | 26 | 8 | 0 |
| Shares Change (YoY) | 2.31% | 0.57% | 47.40% | 227.59% | 33580.72% | - |
| EPS (Basic) | -1.48 | -1.91 | 0.14 | -1.96 | -2.24 | -883.28 |
| EPS (Diluted) | -1.49 | -1.91 | 0.14 | -1.96 | -2.24 | -883.28 |
| Free Cash Flow | -62.09 | -56.34 | -20.57 | -33.73 | -11.32 | -18.81 |
| Free Cash Flow Per Share | -1.59 | -1.47 | -0.54 | -1.30 | -1.43 | -801.48 |
| Gross Margin | -201.19% | - | 5.26% | - | -198.42% | - |
| Operating Margin | -417.20% | -10024.69% | -6.43% | -15380.60% | -347.79% | -331.46% |
| Profit Margin | -386.31% | -9145.51% | 11.95% | -18979.48% | -367.27% | -302.84% |
| Free Cash Flow Margin | -414.79% | -7024.69% | -46.01% | -12585.45% | -234.83% | -274.80% |
| EBITDA | -59.84 | -78.17 | -1.75 | -40.82 | -16.56 | -22.52 |
| EBITDA Margin | - | - | -3.92% | - | - | - |
| D&A For EBITDA | 2.61 | 2.23 | 1.12 | 0.4 | 0.21 | 0.17 |
| EBIT | -62.45 | -80.4 | -2.87 | -41.22 | -16.77 | -22.69 |
| EBIT Margin | - | - | -6.43% | - | - | - |
| Revenue as Reported | 14.97 | 0.8 | 44.7 | 0.27 | 4.82 | 6.85 |
Source: S&P Capital IQ. Standard template. Financial Sources.